Tag:
erectile dysfunction
Latest Headlines
Latest Headlines
Vivus gets ED drug approval, spurring fresh talk of a deal
Vivus has won its first drug approval. The FDA issued word this afternoon that it had stamped its OK on Stendra (avanafil), an erectile dysfunction treatment designed to spur a quicker response for men.
Ampio to seek foreign OKs for premature ejaculation drug
Ampio Pharmaceuticals ($AMPE) is gearing up to seek international regulatory approval for its drug to treat premature ejaculation. The company disclosed Dec. 5 that it is preparing for this, in part,
Lilly's ED treatment Cialis wins prostate indication
Eli Lilly ( $LLY ) just won FDA approval for an enlarged-prostate treatment. That's a bit of good news that only goes so far, as the market for benign prostatic hyperplasia treatments is rather full.
Viagra 2.0: Delivered via nanotech patch?
Viagra delivered via a patch with nanocarriers might work better than the blue pill for erectile dysfunction, according to researchers in Egypt. While oral delivery does work, there is too long a
Vivus readies NDA as Ph3 trial hits goals for ED drug
Mountain View, CA-based Vivus ( $VVUS ) says that its experimental erectile dysfunction drug avanafil hit its goals in a Phase III study. And Vivus, which has been struggling to respond to the FDA's
ED drugmakers look to new formulations
When the patent cliff looms, what do makers of erectile dysfunction remedies turn to? Consumer psychology. As the New York Times reports, Pfizer and Bayer both are reformulating their blockbuster ED
Lilly pushes deeper into men's health
In an effort to become a leader in men's health, Cialis maker Eli Lilly ( NYSE: LLY ) is reporting progress in the battle to help men fight erectile dysfunction. For example, this week the drugmaker
Vivus posts more positive ED data
Vivus is reporting additional results from trial of its ED drug avanafil. Patients who attempted intercourse within 15 minutes of dosing were successful 67 percent, 69 percent and 72 percent of the
On a hot streak, Vivus posts positive ED data
Vivus' experimental therapy for erectile dysfunction hit its endpoints in a Phase III trial, leaving the developer on track for a 2011 FDA filing and igniting a rally for shares that are now up 61
Safety concerns force delay for Phase III ED trial
With regulators at the FDA waving a red flag over safety concerns, King Pharmaceuticals and Palatin Technologies announced that they will delay the planned launch of a Phase III trial of
